The aim of this study was to evaluate whether the combination of VNR + DIF is a more effective treatment compared with the standard platinum-based chemotherapy in EGFR-mutated lung adenocarcinoma patients, and then to clarify the underlying mechanism by which VNR + DIF was efficacious in such patients. Here, EGFR is linked to lung adenocarcinoma.